High Throughput Screening Market to grow at a CAGR of 10.42% during 2025 to 2035; Driven by Rising Drug Discovery Activities and Increasing Demand for Advanced Screening Technologies

Market Research Future (MRFR) published an updated report on the global High Throughput Screening Market, valuing the market at USD 27.42 billion in 2025 and projecting it to grow to USD 30.21 billion in 2026, reaching USD 70.18 billion by 2035 at a compound annual growth rate (CAGR) of 10.42% during the forecast period 2025--2035.

R&D budgets dedicated to precision medicine, government-backed initiatives such as the US NIH funding pipeline, and the rapid transition from manual pipetting workflows to integrated robotics, lab-on-a-chip systems, and AI-guided analysis engines. Buyers in this space are no longer experimenting with automation—they are standardizing around it.

Market Overview

The need to reduce the time it takes to discover new drugs and to improve the quality of candidate selection has made high-throughput screening a strategic imperative for biopharmaceutical and biotechnology companies around the world. The combination of AI-enabled automation, 3-D physiologically relevant tests and microfluidic downsizing is transforming the way laboratories approach discovery workflows, generating a fertile growth environment for instrument, reagent and software providers globally.

North America dominates the global market with a share of around 36.8% due to dense biopharma clusters and CDMO capacity. Europe accounts for roughly 28.9% of the worldwide share, driven by non-animal testing standards. Asia-Pacific is considered the fastest-expanding region with a CAGR of 12.85%, driven by domestic biotech capacity expansion and strategic outsourcing growth.

Key Market Trends & Growth Drivers

• AI-Enabled Screening Automation: Machine learning is now integrated into the screening procedure instead of being a part of it. Integration of automated compound library screening and predictive hit-ranking algorithms on one platform has greatly reduced hit-to-lead times. The NIH Strategic Plan for Data Science emphasizes federal infrastructure support for cross-disciplinary training and the sustainability of AI software.


• Precision Medicine R&D Expansion: Spending on targeted therapeutics by biopharma continues to increase, with industry R&D outlays heavily concentrated around complex oncology and rare-disease indications. The infrastructure need is also further supported by the Horizon Europe Cluster 1 (Health) framework of the European Commission, which is funded by a multi-billion Euro allocation until 2027.

• Three-Dimensional and Physiologically Relevant Assays: Flat monolayer cultures are being replaced with organoids, spheroids and tissue-mimetic systems, which are significantly more predictive of in vivo response. The FDA Modernization Act 2.0 has compelled labs to take up these advanced assay formats faster than the labs had expected.

• Strategic Outsourcing to CDMOs: The fastest-growing end-user segment is contract development and manufacturing organizations at a 12.62% CAGR as sponsors outsource more target-based hit identification to specialized partners with scale and advanced biochemical assay platforms.


• Microfluidic uHTS Venture Investment: Microfluidic uHTS startups raised more than USD 1.2 billion in disclosed funding between 2023–2025. Assays at the nanoliter scale reduce reagent use and enable screening in smaller labs and point-of-care settings, extending access beyond huge pharmaceutical campuses.

Market Segmentation Insights

By Technology: The single largest technology category is cell-based assays, accounting for about 41.2% market share in 2025, offering biologically relevant readouts not possible with purely biochemical formats. The lab-on-a-chip and microfluidic platforms are the fastest-growing technology segment with a CAGR of 11.31% due to reduction in reagent costs and miniaturized workflows. An estimated USD 4.6 billion came from ultra-high-throughput screening systems in 2025.

By Application: Primary and secondary screening contribute the largest portion of the screening leads, around 49.7%, since it is the unavoidable initial filter of any discovery campaign processing millions of compounds. Toxicology and ADME is the fastest-growing application at a CAGR of 12.74%, directly driven by regulatory momentum favoring non-animal safety evaluation.

By End User: Pharmaceutical and biotechnology industries account for ~44.9% in 2025, conducting substantial in-house screening to feed proprietary pipelines. The market is moving towards outsourced discovery services, and CDMOs are the fastest-expanding end-user segment at a CAGR of 12.62%.

By Product & Service: Reagents, kits and consumables were predicted at USD 11.3 billion in 2025, offering the most resilient revenue source as recurring per-test consumption. In terms of product mix, instruments dominate while software and services are the fastest expanding segment as manufacturers convert one-time hardware buyers into long-term platform subscribers.

Regional Landscape

North America -- Biopharma R&D and CDMO Leader

North America has the largest portion of the global market share in the High Throughput Screening Market, with around 36.8%. Growth in the region is being driven by intensive biopharma activity, the deepest pool of contract discovery capability internationally and NIH funding pipelines. The US is the biggest region in terms of revenue, aided by the FDA modernization policy, which promotes the use of sophisticated assays. Canada has a good university-linked research base, whereas Mexico is becoming a near-shore CDMO hub for North American sponsors.

Europe -- Non-Animal Testing and Organoid Innovation

Europe represents roughly 28.9% of the world market, and the region is firmly affected by regulation. The EU’s proactive position on non-animal testing and sustainable laboratory practice has moved laboratories to advanced cell-based and 3-D assay technologies more quickly than commercial pressure alone would dictate. Germany and the UK together represent the majority of regional demand, underpinned by mature pharmaceutical infrastructure and world-leading genomics initiatives. In October 2024, the European Commission granted extra Horizon Europe funds to non-animal testing infrastructure.

Asia-Pacific -- Fastest-Growing Discovery Engine

Asia-Pacific is the fastest-growing region with a CAGR of 12.85% due to national biotech incentive programs and rapid CDMO capacity expansion. India and China are taking the lead, driven by government-sponsored precision medicine financing and a wave of strategic outsourcing that pulls screening volume from Western sponsors. Japan provides a mature, stable revenue base, while South Korea’s government-backed precision medicine investment accelerates platform adoption.

Middle East and Africa -- Emerging Research Infrastructure

The Middle East and Africa area is gaining a growing part of the worldwide market, led by Saudi Arabia’s Vision 2030 diversification program that is funneling funds into life-sciences research facilities and the UAE’s status as a regional biotech hub. South Africa boasts the most developed academic screening capacity on the continent and serves as an anchor for target-based hit identification research.

Competitive Landscape

The High Throughput Screening Market is moderately consolidated with an estimated HHI in the 900-1,100 range and a near 48% share of top five revenue. The structure leaves room for specialized micro-fluidic and informatics players to compete with diversified instrument leaders. The landscape is best described as moderately fragmented with active technology refresh cycles. Some of the major players are Thermo Fisher Scientific, Danaher (Beckman Coulter), Agilent Technologies, PerkinElmer (Revvity), Merck KGaA, Tecan Group, Bio-Rad Laboratories, Corning Incorporated, Hamilton Company, Sartorius AG, and Aurora Biomed. Recent key developments have been:

• Thermo Fisher Scientific’s AI-integrated high-content screening platform introduced in March 2024 is expected to reduce time to hit identification, suggesting rising competition in automated discovery.


• In May 2023, Revvity rebranded from PerkinElmer and expanded its high-content portfolio, combining Opera Phenix Plus and Operetta CLS systems with advanced 3D image analysis software modules optimized for organoids and spheroids


• Danaher finalized the acquisition of Abcam plc for USD 5.7 billion in December 2023, extending its life sciences portfolio with protein research tools and antibodies.


• In May 2025, Tecan Group announced a strategic partnership with a CDMO network to implement standardized automated screening workflows at multiple sites.


• In September 2024, Agilent Technologies launched a label-free biochemical assay platform for target-based hit identification in oncology discovery.


• Sartorius AG introduced in February 2025 a live-cell screening system for sustainable, low-reagent operation to address green-lab procurement trends.

Future Outlook

The High Throughput Screening Market is predicted to be transformed by 2035 due to increasing capabilities of autonomous screening operations, increasing commercialization of microfluidic uHTS platforms and deepening footprint in the rising markets of Asia-Pacific, Middle East and Africa. Organizations that value platform economics and recurring revenue models, integrated discovery-as-a-service offerings, and sustainability- aligned green laboratory practices are positioned for disproportionate growth.

As per the MRFR report, the key growth opportunities include the adoption of AI-driven analytics for better hit identification insights, the creation of unified SaaS and data monetization models, and customized product expansion in high-growth emerging markets through localized service, training, and financing models.